Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Kanz

Showing results (21-30 of 241) with videos related to

Pageof 25
Sort By:
British Journal of Haematology|October 1, 1991
Combination of cytokines: current status and future prospectsL Kanz, W Brugger, K Bross, et al.
Stem Cells (Dayton, Ohio)|April 1, 2000
Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC)W Vogel, S Scheding, L Kanz, et al.
Experimental Hematology|November 8, 2001
Dendritic cells in cancer vaccinesP Brossart, S Wirths, W Brugger, et al.
Annals of the New York Academy of Sciences|July 19, 2001
Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factorsR Möhle, F Bautz, C Denzlinger, et al.
Der Urologe. Ausg. A|January 15, 1999
[Late toxicity after chemotherapy of malignant testicular tumors]A Jakob, C Kollmannsberger, L Kanz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 1985
Identification of B cells in multilineage hematopoietic colonies derived from cells of patients with lymphocytic lymphomaA A Fauser, L Kanz, G W Löhr
Drugs|February 17, 1998
Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospectsH Hebart, L Kanz, G Jahn, et al.
Klinische Wochenschrift|April 1, 1987
Human megakaryocytic progenitor cellsL Kanz, G W Löhr, A A Fauser
Bone Marrow Transplantation|May 17, 2005
Expansion of cord blood CD34+ hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid cultureS Yildirim, A M Boehmler, L Kanz, et al.
Rheumatology International|June 15, 2007
B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selectionJ C Henes, C Richter, L Kanz, et al.
Pageof 25

Showing results (21-30 of 241) with videos related to

Sort By:
Pageof 25
British Journal of Haematology|October 1, 1991
Combination of cytokines: current status and future prospectsL Kanz, W Brugger, K Bross, et al.
Stem Cells (Dayton, Ohio)|April 1, 2000
Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC)W Vogel, S Scheding, L Kanz, et al.
Experimental Hematology|November 8, 2001
Dendritic cells in cancer vaccinesP Brossart, S Wirths, W Brugger, et al.
Annals of the New York Academy of Sciences|July 19, 2001
Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factorsR Möhle, F Bautz, C Denzlinger, et al.
Der Urologe. Ausg. A|January 15, 1999
[Late toxicity after chemotherapy of malignant testicular tumors]A Jakob, C Kollmannsberger, L Kanz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 1985
Identification of B cells in multilineage hematopoietic colonies derived from cells of patients with lymphocytic lymphomaA A Fauser, L Kanz, G W Löhr
Drugs|February 17, 1998
Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospectsH Hebart, L Kanz, G Jahn, et al.
Klinische Wochenschrift|April 1, 1987
Human megakaryocytic progenitor cellsL Kanz, G W Löhr, A A Fauser
Bone Marrow Transplantation|May 17, 2005
Expansion of cord blood CD34+ hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid cultureS Yildirim, A M Boehmler, L Kanz, et al.
Rheumatology International|June 15, 2007
B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selectionJ C Henes, C Richter, L Kanz, et al.
Pageof 25